Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s industry-leading personalized MRD technology (Haystack MRD™) to help evaluate therapeutic response and provide molecular insights for

SECAUCUS, N.J., June 21, 2023 /PRNewswire/ — Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology. Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based

SOURCE Quest Diagnostics Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack’s highly sensitive minimal-residual disease cancer-detection technology to be combined with Quest’s oncology, genomics and pathology expertise and scale, including solid tumor sequencing,

Haystack’s co-founder and Chief Innovation Officer, Josh Cohen, will be participating in a panel discussion at the upcoming Precision Medicine World Conference (PMWC) in Silicon Valey, CA. The panel, “Liquid Biopsy for Minimal Residual Disease,” will take place on January 26 and